A new biotech firmed has joined the fight against some of the most debilitating diseases afflicting millions. Parkinson’s, Alzheimer’s and amyotrophic lateral sclerosis (ALS) are being targeted for new treatments by Yumanity. For now, the company’s footprint is small, though its pedigree is massive.
With five employees, the company was started by Tony Coles. If you’re trying to place the name, he’s the chief executive that sold Onyx Pharmaceuticals to Amgen for $10.4 billion. It’s safe to say the company isn’t hurting for startup capital.